Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NeuroPace (NPCE) Cash & Equivalents (2020 - 2025)

NeuroPace has reported Cash & Equivalents over the past 6 years, most recently at $21.7 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $21.7 million for Q4 2025, up 61.52% from a year ago — trailing twelve months through Dec 2025 was $21.7 million (up 61.52% YoY), and the annual figure for FY2025 was $21.7 million, up 61.52%.
  • Cash & Equivalents for Q4 2025 was $21.7 million at NeuroPace, up from $20.6 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for NPCE hit a ceiling of $31.2 million in Q2 2021 and a floor of $5.7 million in Q3 2022.
  • Median Cash & Equivalents over the past 5 years was $13.6 million (2021), compared with a mean of $15.3 million.
  • Biggest five-year swings in Cash & Equivalents: soared 212.5% in 2021 and later plummeted 81.75% in 2022.
  • NeuroPace's Cash & Equivalents stood at $19.2 million in 2021, then crashed by 65.58% to $6.6 million in 2022, then skyrocketed by 173.4% to $18.1 million in 2023, then decreased by 25.63% to $13.4 million in 2024, then skyrocketed by 61.52% to $21.7 million in 2025.
  • The last three reported values for Cash & Equivalents were $21.7 million (Q4 2025), $20.6 million (Q3 2025), and $22.9 million (Q2 2025) per Business Quant data.